AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pharvaris Shares Soar 10.94% on RAPIDe-3 Study Update
Generated by AI AgentAinvest Pre-Market Radar
Friday, Jul 11, 2025 7:40 am ET1min read
Pharvaris shares surged 10.94% in pre-market trading on July 11, 2025, driven by significant updates regarding its pivotal Phase 3 RAPIDe-3 study.
Pharvaris has revised the timeline for announcing topline data from its RAPIDe-3 study, now expecting the results in the fourth quarter of 2025. This delay is part of a strategic move to ensure the data is robust and compelling, which could support a New Drug Application submission to the FDA in the first half of 2026.
The company's decision to push back the data release has been met with mixed reactions from investors. While some view it as a prudent step to enhance the chances of regulatory approval, others are concerned about the potential impact on the stock price in the interim.
Despite the delay,
remains optimistic about the potential of deucrictibant immediate-release capsule as a treatment for hereditary angioedema (HAE). The company's focus on delivering high-quality data underscores its commitment to advancing this innovative therapy.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Serve Robotics Surges 5.16% as Trump Admin Boosts Robotics Push, Eyes 10X Revenue by 2026
Dec.12 2025
New Pacific Metals (NPM) Soars 7.98% as Base Metals Market Anticipates Supply/Demand Shifts
Dec.12 2025
Gevo Inc. (GEVO) Surges 6.22% on $26M BioRecro Partnership to Expand Carbon Management Capabilities
Dec.12 2025
Sable Offshore Soars 5.82% as Private Placement and Policy Tailwinds Drive Pre-Market Rally
Dec.12 2025
Mastercard Inc. Surges 4.55% as Fintech Optimism and AI Expansion Drive Pre-Market Rally
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet